Fifteen-year trends of cardiogenic shock and mortality in patients with diabetes and acute coronary syndromes
Dauriz M, Morici N, Gonzini L et al.
Am J Med. 2020;133(3):331-339.e2
Leggi
Blu
Le Breaking News di colore blu sono relative ad abstract di articoli originali di particolare rilevanza.
Does metformin interfere with the cardiovascular benefits of SGLT2 inhibitors? Questions about its role as the cornerstone of diabetes treatment
Packer M
American Journal of Medicine. Pub online 12 February 2020
Leggi
Association of glucose-lowering medications with cardiovascular outcomes: an umbrella review and evidence map
Jianhong Z, Xiaoxia Y, Zheng Y, et al.
Lancet Diabetes Endocrinol. 2020;8(3):192-205
Leggi
Time-varying risk of microvascular complications in latent autoimmune diabetes of adulthood compared with type 2 diabetes in adults: a post-hoc analysis of the UK Prospective Diabetes Study 30-year follow-up data (UKPDS 86)
Maddaloni E, Coleman RL, Agbaje O, et al.
Lancet Diabetes Endocrinol. 2020;8(3):206-15
Leggi
Glucose time in range, time above range, and time below range depend on mean or median glucose or HbA1c, glucose coefficient of variation, and shape of the glucose distribution
Rodbard D
Diabetes Technol Ther. Pub online 18 February 2020
Leggi
Switching from suspend-before-low insulin pump technology to a hybrid closed-loop system improves glucose control and reduces glucose variability: a retrospective observational case–control study
Lepore G, Scaranna C, Corsi A, et al.
Diabetes Technol Ther. Pub online 11 February 2020
Leggi
Renal outcomes with the newer antidiabetes drugs: the era before and after CREDENCE
Rajani A, Sahay M, Bhattacharyya A, Amar A
Diabet Med. Pub. online 3 February 2020
Leggi
Sex differences in metabolic regulation and diabetes susceptibility
Tramunt B, Smati S, Grandgeorge N, et al.
Diabetologia. 2020;63:453-61
Leggi
Preterm birth and risk of type 1 and type 2 diabetes: a national cohort study
Crump C, Sundquist J, Sundquist K
Diabetologia. 2020;63:508-18
Leggi
Effects of once-weekly semaglutide vs once-daily canagliflozin on body composition in type 2 diabetes: a substudy of the SUSTAIN 8 randomised controlled clinical trial
McCrimmon RJ, Catarig AM, Frias JP, et al.
Diabetologia. 2020, 63:473–485
Leggi